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Despite substantial progress in early detection and treatment,
breast cancer remains the second commonest malignancy in the
female population. It affects approximately 1 in 10 women and
is responsible for 23.7% of all cancer deaths (Breast Cancer
Statistics, 2000). Comprehensive research has been conducted to
identify clinically useful prognostic factors in primary breast
cancer, with special efforts to identify among node-negative (N–)
patients those with an aggressive phenotype who need adjuvant
systemic treatments and those with indolent tumours who are
likely to be cured by local–regional therapy. A unique, highly
discriminating prognostic factor has not yet been proposed and,
in consideration of the complex biology of the neoplasm, it is
unlikely that one will be identified, although novel promising
prognosticators are emerging. Moreover, sufficient and univocal
evidence has not yet been provided for assessing either the prog-
nostic strength of biological markers or their actual clinical
impact. In fact, a few studies have evaluated the adjunctive contri-
bution of novel factors to already validated scores proposed for
breast cancer and based on different morphopathobiologic features
of proven prognostic utility (Altman and Lyman, 1998; Goldhirsch
et al, 1998; Hayes et al, 1998). 
The Nottingham prognostic index (NPI) can be considered a
gold standard for prognosis since it is based on morphopathologic
features such as lymph node stage, tumour size and histologic
grading of malignancy. It has been prospectively validated in several
studies and has proved to maintain over time a valuable discrimi-
nating power in differentiating patients in low-, intermediate- and
high-risk subsets (Haybittle et al, 1982; Galea et al, 1992; Balslev
et al, 1994). Although lymph node stage has a pivotal role in the
NPI definition, NPI is a validated prognostic discriminator also
in N– patients (Saurbrei et al, 1997) and can be considered as a
baseline reference for the evaluation of the additional prognostic
role of biological variables. 
Experimental studies have suggested tumour-induced neoangio-
genesis as an important step in the evolution of malignant tumours
(Ellis and Fidler, 1996; Yosiji et al, 1996). Recent clinical
evidence indicates that its evaluation, either as microvessel count
or as vascular endothelial growth factor (VEGF) content, signifi-
cantly contributes to identify patients with a worse prognosis,
mainly within the N– subset (Gasparini, 1996; Heimann et al,
1996) but also within endocrine adjuvant setting (Linderholm et al,
2000). Since steroid receptor content is currently used in clinical
practice and tumour proliferative activity is a recognized prog-
nostic factor in N– patients (Hayes et al, 1998), the aim of the
present study was to evaluate the adjunctive prognostic contribu-
tion of intratumour VEGF concentration to a widely adopted prog-
nostic classification (NPI), taking into account the effect of steroid
receptors and cell proliferation. For evaluation of the prognostic
impact of VEGF concentration in the continuous scale of measure-
ment, flexible regression and bootstrap techniques have been
adopted. 
MATERIALS AND METHODS 
The present study was carried out on a series of 226 N– primary
breast cancer patients subjected, between May 1991 and May
1993, only to radical or conservative surgery plus radiotherapy and
to complete axillary dissection until relapse and followed up
for a median of 75 months (range, 4–98) at the Istituto Nazionale
Tumori of Milan. Information on the cases was also available for
steroid receptors, evaluated by the dextran-coated charcoal tech-
nique (Ronchi et al, 1986), and tumour proliferative activity,
expressed as the thymidine labelling index (TLI) (Silvestrini et al,
1995). The NPI was determined according to Elston and Ellis
(1991). 
VEGF expression was measured by a quantitative enzyme
immunoassay technique. The role of NPI, VEGF, oestrogen and
progesterone (ER, PgR) content, and TLI on disease-free survival
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distant metastasis or contralateral tumours; 63 events) was investi-
gated by the Cox model, once the proportional hazard assumption
was verified (Grambsch and Therneau, 1994). On the basis of
prior knowledge, only linear terms were considered for ER, PgR
and TLI after logarithmic transformation (Silvestrini et al, 1996).
For VEGF, a restricted cubic spline transformation (Durrleman
and Simon, 1989) was initially considered on its logarithmic
values, whereas only the linear term was finally adopted. Among
pre-specified interactions (VEGF × TLI, VEGF × NPI, VEGF ×
ER) only VEGF × ER was selected. The additional prognostic
contribution of biological variables was also evaluated by a boot-
strap re-sampling technique (200 samples) applied to a backward
variable selection, starting from a model including all variables
and the interaction. Model comparisons were performed on the
basis of Akaike Information Criterion (AIC) (Collett, 1994),
considering 3 different penalty factors for the degrees of freedom
(i.e. 2, 3, 4) – the first corresponding to that traditionally used for
AIC and the other 2 allowing for a more conservative selection.
Model predictive ability was measured by Harrell’s c statistic
(Harrell et al, 1996). To illustrate the effect of covariates, the
expected survival curves, calculated from Cox model results, were
plotted according to fixed covariate values. Selected values were
the 25th, 50th or 75th percentiles for VEGF, the 25th or 75th
percentiles for ER, low (1) and intermediate (2) NPI. TLI and PgR
were fixed to the median values of their distributions. 
RESULTS AND DISCUSSION 
The values of VEGF ranged from 0 to 337.3 with 30.7, 57.4, 97.4,
as 25th, 50th, 75th percentiles, respectively. The DFS curves
according to NPI levels are shown in Figure 1A: since only N–
patients were considered, the NPI classification is only a 2-level
score: low and intermediate. The difference between DFS curves
was statistically significant (hazard ratio (HR) for replase: interme-
diate NPI vs low NPI, 1.71; 95% confidence limits (CL), 1.03–2.83;
P = 0.039). In the multivariate regression model (Table 1), using the
conventional penalty factor of 2 for AIC, TLI was retained in the
model in 67.5%, ER in 71.5%, VEGF in 94% and VEGF*ER inter-
action in 66.5% of the bootstrap samples. Moreover, VEGF was
retained in 90.5% and 76.6% of the bootstrap samples with the
increased penalty terms. 
The predictive ability of the model was c = 0.655, whereas
considering NPI only and NPI plus steroid receptors and TLI, the c
statistic dropped to 0.571 and 0.623, respectively. To provide a
graphic display of model results, expected DFS curves were drawn
for selected combinations of variable values (Figure 1B, ER-poor
tumours; Figure 1C, ER-rich tumours). The present findings seems
to suggest a discriminatory effect of VEGF in identifying patients
who differ in prognosis in NPI = 1 and NPI = 2 groups (5-year
probability of relapse for low vs high VEGF: 12% vs 20% and
19% vs 31%, respectively) mainly in ER-poor tumours (Figure 1B).
For these patients, the estimated HR for disease for high vs low
VEGF was 1.79 (95% CL, 1.15–2.79). Conversely, in ER-rich
tumours, i.e., in tumours with an ER content greater than 126 fmol
mg–1 cytosolic protein) (Figure 1C), VEGF was unable to segre-
gate patients with different prognosis, and the HR was 1.18 (95%
CL, 0.78–1.79). In ER-poor tumours angiogenesis might be at an
initial stage and thus the presence of high VEGF levels could indi-
cate the activation of such a process. Conversely, in the ER-rich
subset a functional hormone control seems able to counteract
angiogenesis activation in both NPI groups and, as suggested by a
previous study (Coradini et al, 2000), a longer follow-up could be
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Figure 1 Disease-free survival curves for 226 patients with node-negative
resectable breast cancer. (A) Kaplan–Meier curves according to NPI. 
(B) Expected disease-free survival curves calculated from the Cox multiple
regression model as a function of NPI (1,2) and VEGF (30.7, 57.4, 97.4 pg
mg–1 cytosolic protein, corresponding to the 25th, 50th and 75th percentiles
of the distribution) for patients with ER-poor tumours (17 fmol mg–1 cytosolic
protein, corresponding to the 25th percentile of the distribution). TLI and PgR
are fixed to the median values of their distributions: 2.8% and 68 fmol mg–1
cytosolic protein, respectively. VEGF expression was measured by a
quantitative enzyme immunoassay technique following the manifacturer’s
instruction (CYTimmune Science). Each sample was run in duplicate and
calibration was performed according to the method proposed by O’Connell
et al (1993). (C) Expected disease-free survival curves from the Cox multiple
regression model as a function of NPI and VEGF (30.7, 57.4, 97.4 pg mg–1
cytosolic protein, corresponding to the 25th, 50th and 75th percentiles of the
distribution) for patients with ER-rich tumours (126 fmol mg–1 cytosolic
protein, corresponding to the 75th percentile of the distribution). TLI and PgR
are fixed to the median values of their distributions: 2.8% and 68 fmol mg–1
cytosol protein, respectively 
BJOC 01-2019 795-797  10/9/01  2:13 pm  Page 796necessary to observe the disruption of the hormone-related growth
control and angiogenesis balance. 
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Table 1 Multivariate analysis for disease-free survival 
Model terms b (SE)a Model effects DFb χ 2 c P
Full model 6 14.44 0.0140 
NPI 0.498 (0.277) Factor 1 3.25 0.0715 
ERd 0.788 (0.452) Factor + Interaction 2 3.40 0.1823 
PgRd 0.025 (0.067) Factor 1 0.14 0.7053 
TLId 0.407 (0.242) Factor 1 2.84 0.0918 
VEGFd 1.031 (0.430) Factor + Interaction 2 6.76 0.0340 
VEGFd*ERd –0.183 Interaction 1 3.32 0.0686 
(0.100) 
aEstimated regression coefficient. In parenthesis, standard error. 
bDegree of freedom. 
cWald statistics for model effects. 
dLogarithmic transformation. 
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